MARKET

TLSA

TLSA

Tiziana Life Sciences Ltd Com
NASDAQ
1.140
+0.030
+2.70%
After Hours: 1.120 -0.02 -1.75% 16:55 10/01 EDT
OPEN
1.110
PREV CLOSE
1.110
HIGH
1.190
LOW
1.090
VOLUME
697.70K
TURNOVER
--
52 WEEK HIGH
2.330
52 WEEK LOW
0.7615
MARKET CAP
145.08M
P/E (TTM)
-7.3171
1D
5D
1M
3M
1Y
5Y
1D
Tiziana Seeks FDA Orphan Drug Designation For Intranasal Foralumab
NASDAQ · 1d ago
Tiziana Files For Orphan Drug Designation For Foralumab In MSA
NASDAQ · 1d ago
Tiziana Life Sciences Seeks FDA Orphan Status for Intranasal Foralumab in Multiple System Atrophy
TipRanks · 1d ago
Tiziana Life submits request to U.S. FDA for ODD for intranasal foralumab
TipRanks · 1d ago
Tiziana Begins Phase 2a BANYAN Trial Of Intranasal Foralumab In ALS Patients
NASDAQ · 3d ago
Tiziana Life Sciences Doses First Participants in Phase 2a ALS BANYAN Trial of Intranasal Foralumab
TipRanks · 3d ago
Tiziana Life announces first 3 participants received first dose in ALS BANYAN
TipRanks · 3d ago
Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial
Benzinga · 3d ago
More
About TLSA
Tiziana Life Sciences Ltd. is a biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Its clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer’s, and Amyotrophic lateral sclerosis. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Webull offers Tiziana Life Sciences Ltd - ADR stock information, including NASDAQ: TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.